Cite
Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan
MLA
Nakane, Keita, et al. “Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan.” Cancers, vol. 16, no. 15, Aug. 2024, p. 2648. EBSCOhost, https://doi.org/10.3390/cancers16152648.
APA
Nakane, K., Taniguchi, K., Nezasa, M., Enomoto, T., Yamada, T., Tomioka-Inagawa, R., Niwa, K., Tomioka, M., Ishida, T., Nagai, S., Yokoi, S., Taniguchi, T., Kawase, M., Kawase, K., Iinuma, K., Tobisawa, Y., & Koie, T. (2024). Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan. Cancers, 16(15), 2648. https://doi.org/10.3390/cancers16152648
Chicago
Nakane, Keita, Kazuki Taniguchi, Minori Nezasa, Torai Enomoto, Toyohiro Yamada, Risa Tomioka-Inagawa, Kojiro Niwa, et al. 2024. “Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan.” Cancers 16 (15): 2648. doi:10.3390/cancers16152648.